Long Position on SPRY @ $14.50 on 9/20/2024 (Fundamentals)

ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions.

The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Entry Point: $14.50

Trading Range: $3.35 - $16.50

Stop Loss: $13.75

Target Price: $15.75

Position closed on 10/16/2024 at price of $16.52 with a 13.93% gain in 26 days.

Back to Portfolio